Analyst Ratings For Shire PLC (ADR) (NASDAQ:SHPG)
Today, Cantor Fitzgerald set its price target on Shire PLC (ADR) (NASDAQ:SHPG) to $222.00 per share.
There are 12 Buy Ratings, 5 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Shire PLC (ADR) (NASDAQ:SHPG) is Buy with a consensus target price of $201.1538 per share, a potential 17.20% upside.
Some recent analyst ratings include
- 5/11/2018-Kepler Capital Markets Reiterated Rating of Buy .
- 4/29/2018-BTIG Research Reiterated Rating of Buy.
- 3/28/2018-Bank of America Reiterated Rating of Buy.
About Shire PLC (ADR) (NASDAQ:SHPG)
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Shire PLC (ADR) (NASDAQ:SHPG)
Shares of Shire PLC (ADR) closed the previous trading session at 171,35 up +1,61 0,95 % with 931571 shares trading hands.
